Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Aptorum Group Ltd Class A (APM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: APM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $80
1 Year Target Price $80
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -90.31% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.22M USD | Price to earnings Ratio - | 1Y Target Price 80 |
Price to earnings Ratio - | 1Y Target Price 80 | ||
Volume (30-day avg) 2 | Beta -0.02 | 52 Weeks Range 0.46 - 4.47 | Updated Date 09/17/2025 |
52 Weeks Range 0.46 - 4.47 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.33% | Return on Equity (TTM) -30.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15696618 | Price to Sales(TTM) 23.35 |
Enterprise Value 15696618 | Price to Sales(TTM) 23.35 | ||
Enterprise Value to Revenue 31.22 | Enterprise Value to EBITDA -0.45 | Shares Outstanding 5346820 | Shares Floating 3404715 |
Shares Outstanding 5346820 | Shares Floating 3404715 | ||
Percent Insiders 19.48 | Percent Institutions 0.82 |
Upturn AI SWOT
Aptorum Group Ltd Class A
Company Overview
History and Background
Aptorum Group Limited was founded in 2016. It focuses on developing and commercializing therapeutic and diagnostic technologies to tackle unmet medical needs.
Core Business Areas
- Therapeutic Programs: Development of therapeutic candidates for infectious diseases and other diseases, including orphan diseases. Focus on small molecule and biologic drug development.
- Diagnostics: Develop diagnostic tools for identifying and managing various diseases, especially focusing on early and rapid diagnostics.
Leadership and Structure
The leadership team consists of experienced executives in pharmaceuticals and biotechnology. The organizational structure is typical of a small biotech company, with departments for R&D, clinical development, and business development.
Top Products and Market Share
Key Offerings
- ALS-4 (SACT-1): A small molecule therapeutic for Staphylococcus aureus infections including MRSA. Currently in clinical development stage. Market share is currently not applicable as the product is not yet commercialized. Competitors include companies developing novel antibiotics, such as Melinta Therapeutics (MLNT) and Nabriva Therapeutics (NBRV).
- Competitors: Melinta Therapeutics, Nabriva Therapeutics
- Competitors: Roche Holding AG, Abbott Laboratories
- RPIDD platform: Rapid pathogen identification and detection diagnostics platform focused on detecting bacterial and fungal infections. Market share is currently not applicable as the product is not yet commercialized. Competitors include companies in diagnostic market, such as Roche Holding AG (RHHBY) and Abbott Laboratories (ABT).
Market Dynamics
Industry Overview
The pharmaceutical and diagnostics industries are highly competitive and regulated. The demand for innovative therapies and diagnostics continues to grow, driven by aging populations and increasing healthcare expenditures.
Positioning
Aptorum Group Ltd is positioned as an innovator in the pharmaceutical and diagnostics space, focusing on unmet medical needs. Their competitive advantage lies in developing novel therapies and diagnostics targeting niche markets.
Total Addressable Market (TAM)
The TAM for infectious disease therapies and diagnostics is estimated to be several billion USD. Aptorum Group Ltd targets specific segments within this market, positioning it for growth as its products advance through clinical development.
Upturn SWOT Analysis
Strengths
- Innovative technologies
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- High dependence on clinical trial outcomes
- Small company, lack of developed manufacturing
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
Threats
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- RHHBY
- ABT
- MLNT
- NBRV
Competitive Landscape
Aptorum Group Ltd faces intense competition from larger pharmaceutical and diagnostic companies. Its success depends on its ability to develop and commercialize innovative products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by R&D progress and securing financing.
Future Projections: Future growth depends on clinical trial successes and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainty in biotech investments.
Recent Initiatives: Recent initiatives include advancing clinical trials and seeking partnerships for commercialization.
Summary
Aptorum Group Ltd is a small biotech company with innovative technologies targeting unmet medical needs. Its success hinges on positive clinical trial outcomes and securing financing. The company faces significant competition from larger, better-resourced companies and regulatory hurdles, making it a high-risk, high-reward investment. The company is focused on expanding their research and partnership opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Articles
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data presented is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be made after conducting thorough due diligence and consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptorum Group Ltd Class A
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-12-18 | Founder, CEO & Executive Director Mr. Chung Yuen Huen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.aptorumgroup.com |
Full time employees 1 | Website https://www.aptorumgroup.com | ||
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.